About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 36 record(s)
Req # NFB_AI_2023-2024_4
The receipts, detailed expense claims and expense reports that the former commissioner of the NFB filed for the following trips: - Jan 9-15, 2017 for the Mission to China 2017 - Nov 1-2, 2017 for the Participation in the Conference of Women of La Francophonie in Bucharest, Romania. - April 5-10, 2018 for the Mission to China 2018 - Oct 15-20, 2019 trip to Frankfurt for the attendance at different events part of the 2019 Frankfurt Book Fair - Oct 18-23, 2021 trip to Frankfurt for the Participation as part of the Canadian mission within the 2021 Frankfurt Book Fair – Canada, Guest of Honour Country . March 16-22, 2022 trip to Dubai for the Participation as part of the Canadian government mission to unveil TRACES, an interactive installation open to the public throughout the world’s fair, from October 1, 2021, to March 31, 2022, at the Canada Pavilion site. - March 31-April 4,2022, trip to Berlin for the Participation in numerous events related to the exposition of Alanis Obomsawin works at the HKW Cultural Centre in Berlin.Organization: National Film Board
152 page(s)
February 2024
February 2024
Req # A-2024-54596
Submission of the Public Health Agency of Canada (PHAC) to the Patented Medicine Prices Review Board’s November 2023 consultation on the Scoping paper of the Board's Guidelines. Submissions from other stakeholders can be viewed here: https://www.canada.ca/en/patented-medicine-prices-review/services/consultations/scoping-paper-board-guidelines.htmlOrganization: Patented Medicine Prices Review Board Canada
7 page(s)
February 2024
February 2024
Req # A-2022-05111
Electronic copies of the following documents. In all cases, cabinet confidences may be excluded and draft versions of documents. In all of the requests below, “draft guidelines” refers to the PMPRB Guidelines that were published for comment on October 6, 2022, or any prior drafts or versions of those 2022 Guidelines (for example, if a draft version was circulated to Health Canada for comment in September 2022, it would be part of the “draft guidelines” for the purpose of this request). • Emails or other communications from Health Canada commenting on the draft guidelines, and that were sent between July 1, 2022, and October 6, 2022. • Emails or other communications from the Board members or Board Chair commenting on the draft guidelines, and that were sent between July 1, 2022, and October 6, 2022. • Any training presentations, training manuals, or summaries of the new guidelines prepared for use by the Board Staff, Board, or other governmental departments prepared between July 1, 2022, and October 6, 2022. • Any documents with calculations of how much prices will decrease under the draft guidelines, or under alternative pricing rules, and that were prepared between January 1, 2022, and October 6, 2022 (note the change in date relative to other requests). • Any documents comparing prices or price reductions under the draft guidelines and the old PMPRB Compendium of Guidelines and Procedures. • Any documents, including legal memos, on the compliance of the draft guidelines with legal decisions about the PMPRB, including Alexion Pharmaceuticals Inc. v. Canada (Attorney General), 2021 FCA 157, Merck Canada c Canada, 2022 QCCA 240, and Innovative Medicines Canada v. Canada (Attorney General), 2020 FC 725. • Any documents which discuss how a medicine’s therapeutic class and comparator products will be established under the draft guidelines. • Any documents showing how the Board Staff arrived at the exact pricing tests discussed in paragraph 33-35 of the draft Guidelines. • Any documents which discuss how Board Staff will assess whether a price is excessive *after* an investigation has been opened. For context, the backgrounder which accompanied the draft guidelines suggested that staff will consider “the totality of the circumstances surrounding the price of the medicine, through the lens of the section 85 factors.Organization: Patented Medicine Prices Review Board Canada
197 page(s)
July 2023
July 2023
Req # A-2023-025211
With regard to the c. 2003 HDAP Report on New Patented Drug - Angiomax (http://www.pmprbcepmb.gc.ca/view.asp?ccid=583), I am looking for a copy of any supporting research, reports and calculations used to determine dosage regimens. I am specifically interested in how these quantities (in mL) were derived, the benchmark patient weight that was used (in kg) and the timeframe of the dosing.Organization: Patented Medicine Prices Review Board Canada
18 page(s)
July 2023
July 2023
Req # A-2023-025599
For FY 2015-2022 (inclusive), how many investigations into prescription pricing on the basis that the pricing exceeded the guidelines resulted in a public hearing? Of those that resulted in a public hearing, in how many was the pricing found to be excessive? Of those that were found to be excessive, how many resulted in orders to reduce the prescription price?Organization: Patented Medicine Prices Review Board Canada
1 page(s)
July 2023
July 2023
Req # A-2023-025896
For fiscal years 2015-2022 (inclusive), how many new patented medicines were reported to the board by Bayer, Inc.? From among those reports, how many included claims that a price exceeded the guidelines?Organization: Patented Medicine Prices Review Board Canada
588 page(s)
July 2023
July 2023
Req # A-2023-025600
For FY 2015-2022 (inclusive), how many Advance Certificate Rulings were issued by the board?Organization: Patented Medicine Prices Review Board Canada
0 page(s)
July 2023
July 2023
Nothing to report this month
Organization: National Film Board
July 2023
Req # AI_2022-2023_3
All documents related to sound experiments in the following projects: The Festival of Britain (1951); Around is Around (1951); Now is the Time (to Put on Your 3D Glasses) (1951); Labyrinth (1967, as part of Expo 67); Expo 67 (Montreal); Expo 70 (Osaka); Tiger Child (1970, as part of Expo 70); IMAX; Stereo soundOrganization: National Film Board
1564 page(s)
February 2023
February 2023
Req # A-2023-02395
Copies of all correspondence and communications between the (then) acting chairperson of the Patented Medicines Prices Review Board Mélanie Bourassa-Forcier and Innovative Medicines Canada (IMC) between October 1, 2022 and December 5, 2022 regarding the PMPRB's new draft guidelines and the consultation process. Please include all responses to Innovative Medicines Canada (IMC)'s communications/correspondence from the (then) acting chairperson of the Patented Medicines Prices Review Board Mélanie Bourassa-Forcier.Organization: Patented Medicine Prices Review Board Canada
19 page(s)
February 2023
February 2023